Orexo: Managed Medicaid contract can compensate Zubsolv-loss in CVS – Dagens Industri

Orexo: Managed Medicaid contract can compensate Zubsolv-loss in CVS

                  2015-08-04 20:36
             

 (SIX) drug delivery company Orexo confirms that CVS Caremark, a  Pharmacy Benefit Manager (PBM) in the United States, removed Orexo  opiate addiction drug Zubsolv from the recommendation list  commercial clients that will apply from 1 January 2016. This means  To Zubsolv not subsidized patients in the insurance  in CVS Caremark, which have "high control over what medicines  patients may be prescribed ".       At the same time, Orexo announces that discussions with "several other"  private and public insurers continues and that it was  has signed a multi-year exclusive agreement with a PBM segment  "Managed Medicaid." The new agreement could "potentially add more  patients to Zubsolv treatment than what might be lost in the  CVS Caremark Marks commercial segments. "       It is clear from a press release.       Orexo believes that patients with the insurance companies that are affected by  the new recommendation list represents "a minority" of the  entire CVS  Care Marks patient population. Orexo estimates that these  insurance of CVS Caremark currently accounts for 10-15 percent of the  current sales, equivalent to 0.6-0.8 percent market share.       During the 18 months Zubsolv has been the only drug  have been subsidized and recommended, in addition to generics, its  main competitor maintained a high market share in CVS Caremark. The  orexo choose to interpret as there is still a possibility that  maintain market share even when Zubsolv is excluded for patients with  insurance companies which have high control on the drugs used.  Orexo believes that Zubsolv has an "excellent platform" to "defend  its market share. "       CVS Caremark Mark's decision "came as a surprise" for Orexo, according to CEO  Nikolaj Sørensen emphasizes that Zubsolv continued to win  market share in the non-exclusive segment of CVS Caremark.       "Although the decision is disappointing, we are pleased with the positive   the development of our market as we see in July in all  customer segments and also has Zubsolv on 'all time high' in  both the sale of the number of tablets and market share, "says  Sørensen.    Johan Eklund, tel +46 31 350 64 87  mailto: johan.eklund@six-group.se  www.blogg.six.seSIXNews  SIX News